Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.75 USD | +1.06% | -0.21% | -7.59% |
Sales 2024 * | 1.06M 88.48M | Sales 2025 * | 170K 14.13M | Capitalization | 128M 10.7B |
---|---|---|---|---|---|
Net income 2024 * | -30M -2.5B | Net income 2025 * | -61M -5.09B | EV / Sales 2024 * | 13.4 x |
Net cash position 2024 * | 114M 9.51B | Net cash position 2025 * | 60.6M 5.05B | EV / Sales 2025 * | 400 x |
P/E ratio 2024 * |
-2.97
x | P/E ratio 2025 * |
-2.43
x | Employees | 37 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.82% |
Latest transcript on Vistagen Therapeutics, Inc.
1 day | +1.06% | ||
1 week | -0.21% | ||
Current month | -10.04% | ||
1 month | +9.20% | ||
3 months | -2.06% | ||
6 months | +56.77% | ||
Current year | -7.59% |
Managers | Title | Age | Since |
---|---|---|---|
Shawn Singh
CEO | Chief Executive Officer | 61 | 01/00/01 |
Cynthia Anderson
DFI | Director of Finance/CFO | 55 | 21/23/21 |
Joshua Prince
COO | Chief Operating Officer | 54 | 01/21/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Jon Saxe
CHM | Chairman | 88 | 01/00/01 |
Jerry Gin
BRD | Director/Board Member | 81 | 01/16/01 |
Shawn Singh
CEO | Chief Executive Officer | 61 | 01/00/01 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.00% | 18 M€ | +3.86% | - |
Date | Price | Change | Volume |
---|---|---|---|
26/24/26 | 4.75 | +1.06% | 194,533 |
25/24/25 | 4.7 | -0.42% | 194,805 |
24/24/24 | 4.72 | -2.28% | 147,555 |
23/24/23 | 4.83 | +1.05% | 189,955 |
22/24/22 | 4.78 | +0.42% | 138,367 |
Delayed Quote Nasdaq, April 27, 2024 at 01:30 am IST
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-7.59% | 128M | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.74B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- VTGN Stock